Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
---|---|---|---|---|---|
PMID:17361017 | IVR | 100 mg/kg/day | 100 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
IVR | 200 mg/kg/day | 200 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
IVR | 100 mg/kg/day | 100 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
IVR | 50 mg/kg/day | 50 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
IVR | 50 mg/kg/day | 50 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
PMID:17964624 | IVR | 100 mg/kg/day | 100 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
IVR | 100 mg/kg/day | 100 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 100 mg/kg/day | 100 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
IVR | 100 mg/kg/day | 100 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
IVR | 3 mg/kg/day | 3 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
IVR | 3 mg/kg/day | 3 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
IVR | 10 mg/kg/day | 10 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
IVR | 10 mg/kg/day | 10 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
PMID:18335096 | IVR | 0.14 mg/kg | 0.14 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
IVR | 0.14 mg/kg | 0.14 mg/kg | Decreased ovarian weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
IVR | 0.14 mg/kg | 0.14 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 0.14 mg/kg | 0.14 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
IVR | 0.7 mg/kg | 0.7 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
IVR | 0.7 mg/kg | 0.7 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
IVR | 0.7 mg/kg | 0.7 mg/kg | Decreased ovarian weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
IVR | 0.7 mg/kg | 0.7 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
IVR | 0.7 mg/kg | 0.7 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
PMID:22233939 | IVTH | 0.00000000000001 - 0.0001 M | 0.0000000001 - 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
IVTH | 0.00000000000001 - 0.0001 M | 0.0000000001 - 0.00000001 M | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
PMID:26217518 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
PMID:27449334 | IVR | 5 mg/kg | 5 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
IVR | 10 mg/kg | 10 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
PMID:28712647 | IVR | 0.2 mg/kg | 0.2 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
IVR | 0.2 mg/kg | 0.2 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
IVR | 0.2 mg/kg | 0.2 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
IVR | 0.2 mg/kg | 0.2 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
PMID:29112739 | IVR | 1 mg/kg | 1 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
IVR | 10 mg/kg | - | No significant effects observed | - | |
PMID:30849655 | IVTH | 0.000001 M | 0.000001 M | Affects liver function | Hepatic endocrine-mediated perturbations |
IVTH | 0.00000001 M | 0.00000001 M | Affects liver function | Hepatic endocrine-mediated perturbations | |
IVTH | 0.0000001 M | 0.0000001 M | Affects liver function | Hepatic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.